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cancer.  Results: Two hundred and thirteen responses were 
received and 153 entries were valid for analysis. Of those, 
63.4% came from an academic institution, 51% were oncolo-
gists, and 52% treated more than 25 cases per year. A major-
ity of responses (71%) were from Italy (40%), Germany (23%), 
and Spain (8%). As first-line therapy, 11% used gemcitabine 
+/– erlotinib, 42% used FOLFIRINOX, and 47% used gem-
citabine + nab-paclitaxel. Of the intensified regimens, both 
were applied to equal parts, but the likelihood of protocol 
deviation was higher when using  FOLFIRINOX ( p   < 0.01). 
FOLFIRINOX was considered more toxic than gemcitabine + 
nab-paclitaxel (neutropenia 88 vs. 68%; polyneuropathy 42 
vs. 41%; rapid deterioration 42 vs. 31%).  FOLFIRINOX was rat-
ed to achieve longer survival with an acceptable quality of 
life (52 vs. 44%). Moreover, 57% of participants thought that 
gemcitabine + nab-paclitaxel should be the backbone for 
further clinical trials in pancreatic cancer.  Conclusion: Inten-
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 Abstract 
 Introduction: Recently, FOLFIRINOX and gemcitabine + 
nab-paclitaxel have been introduced as a novel intensified 
chemotherapy regimen for patients with metastasized pan-
creatic cancer. This study aims to analyze the real-world clin-
ical practice with FOLFIRINOX and gemcitabine + nab-pacli-
taxel across Europe.  Methods: Invitations to participate in an 
anonymous web-based questionnaire were sent via e-mail 
to 5,420 doctors in 19 European countries through the net-
work of national gastroenterological, oncological, surgical 
and pancreatic societies as well as the European Pancreatic 
Club. The questionnaire consisted of 20 questions, 14 re-
garding the use of intensified chemotherapy, 4 regarding 
demographics of the participants, and 1 to verify the active 
involvement in the management of metastatic pancreatic 
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sified chemotherapy is widely used in pancreatic cancer pa-
tients in Europe following its recent clinical approval. Inter-
estingly, nab-paclitaxel and  FOLFIRINOX were used at com-
parable frequency although the latter had to be de-escalated 
more often.  © 2016 S. Karger AG, Basel 
 Introduction 
 Pancreatic ductal adenocarcinoma (PDAC) is a major 
cause of cancer-related mortality in Europe and the Unit-
ed States. By 2030, PDAC is projected to become the sec-
ond leading cause of cancer-related deaths next to lung 
cancer in the United States  [1] . Eighty percent of patients 
never qualify for potentially curative surgery and ap-
proximately half of the patients present with distant me-
tastasis at the time of diagnosis. The overall 5-year sur-
vival rate is less than 5%, accounting for a number of 
85,300 predicted deaths in Europe in 2015 with rising 
incidence  [2] ; this kind of a situation is considered a 
medical emergency  [3] . For metastatic pancreatic cancer, 
which makes up for approximately half of all newly diag-
nosed cases, there are currently 3 chemotherapeutic reg-
imens available which, by international consensus, are 
considered first-line treatment options  [4] . Gemcitabine 
is a nucleoside analogue that was approved almost 20 
years ago and it exerts a moderate survival benefit over 
untreated patients and was mostly used for its clinical 
benefit  [5, 6] . In the mid-2000 period, the addition of er-
lotinib, an epidermal growth factor receptor inhibitor, 
was shown to mediate a significant but clinically irrele-
vant survival benefit of approximately 2 weeks  [7] . How-
ever, a small subgroup of patients with severe rash (grade 
 ≥ 2) benefited most (10.5 months) from the addition of 
erlotinib  [8, 9] . FOLFIRINOX, a gemcitabine-free com-
bination protocol utilizing 5-fluorouracil, leucovorin, 
irinotecan, and oxaliplatin was the first so-called intensi-
fied chemotherapy regimen that showed a clinically rel-
evant increase in survival when compared to gemcitabine 
monotherapy (11.1 vs. 6.8 months; hazard ratio for death, 
0.57; 95% CI 0.45–0.73;  p  < 0.001)  [10, 11] . The almost 
doubling of survival time can be considered a hallmark 
in oncology and has since been introduced in daily clini-
cal practice. However, due to its higher toxicity profile in 
studies, it is unclear which subgroup of patients truly 
benefits from this regimen. The latest innovation in the 
treatment of palliative pancreatic cancer patients was the 
successful clinical introduction of nab-paclitaxel, a 
nanoparticle-sized albumin-bound paclitaxel, in combi-
nation with gemcitabine. The combination resulted in a 
significant increase in survival when compared to gem-
citabine alone (8.5 vs. 6.7 months, hazard ratio for death, 
0.72; 95% CI 0.62–0.83;  p  < 0.001)  [12, 13] . Although not 
directly comparable due to methodological differences of 
the phase III trials, gemcitabine + nab-paclitaxel ap-
peared to be less toxic than FOLFIRINOX. Therefore, 
healthcare providers have oftentimes the difficult task of 
choosing one of 3 regimens, which are all considered 
first-line options. This questionnaire study aims to inves-
tigate the current practice and decision-making process 
of physicians who are treating patients with metastatic 
pancreatic cancer in Europe for the first time.
 Methods 
 This is a web-based questionnaire study that aimed to under-
stand the current practice in the use of intensified chemotherapy 
for treatment of metastatic pancreatic cancer under real-life con-
ditions in Europe. The questionnaire was written in English and 
was available online from June 1st 2015 through November 30th 
2015. Invitations where sent via e-mail through the network of 
national gastroenterological, oncological, surgical, and pancre-
atic societies of 20 European countries as well as the European 
Pancreatic Club. In total, 5,420 individual emails were sent. In 
October 2015, a reminding e-mail was sent to the same list of 
recipients. At the beginning of the questionnaire, participants 
were asked whether they were actively involved in treating met-
astatic pancreatic cancer and if the answer was no, those re-
sponders were not asked any further questions. The question-
naire contained 4 demographic questions regarding the country 
of practice, specialty, healthcare setting, and disease-specific case 
load of the responders, followed by 14 questions regarding their 
current practice in using intensified chemotherapy for metastat-
ic pancreatic cancer. All questions could be answered by choos-
ing from a dropdown menu or by clicking on predefined options, 
there was no need to enter text. In 5 cases, however, open fields 
for alternative answers were provided. In some cases, multiple 
answers were accepted. The name and institution of the partici-
pants were not recorded. The analysis was conducted using Mi-
crosoft Excel 2016 and Prism 5. The full questionnaire can be 
viewed online (online suppl. Fig.  1, see www.karger.com/
doi/10.1159/000453257).
 Results 
 Frequency of Intensified Chemotherapy Use across 
Europe 
 A total of 213 individuals responded by filling in the 
questionnaire sent to them via e-mail and this resulted in 
an overall response rate of 3.9%. Out of those, 55 an-
swered that they were not actively treating patients with 
 Le/Vinci/Schober/Krug/Javed/Kohlmann/
Sund/Neesse/Beyer 
Digestion 2016;94:222–229
DOI: 10.1159/000453257
224
metastatic pancreatic cancer and another 5 gave invalid 
answers in terms of their country of origin; therefore, they 
were excluded, leaving 153 questionnaires for further 
analysis. The distribution by country, specialty, hospital 
setting, and annual case load is shown in  Tables 1 ,  2 and 
 Figure 1 a. As first-line therapy, 11% of participants cur-
rently used gemcitabine +/– erlotinib, 42% used 
 FOLFIRINOX, and 47% used gemcitabine + nab-pacli-
taxel ( Fig. 1 b). While 45% responded that they would use 
intensified chemotherapy (FOLFIRINOX or gem-
citabine + nab-paclitaxel) in more than half of their pa-
tients, 37% said that they would use intensified chemo-
therapy in 25–50% and 18% said that they would use it in 
less than 25% of cases. The 3 most frequently mentioned 
criteria for choosing one of the 2 intensified regimens 
over gemcitabine +/– erlotinib were the patients’ perfor-
mance status (34%), personal experience (23%), and cur-
rent guidelines (22%). Interestingly, when asked which of 
the 2 regimens were preferred, 50% responded in favor of 
FOLFIRINOX ( n = 76) and the other half in favor of gem-
citabine + nab-paclitaxel ( n = 77). The 3 most frequently 
given reasons for choosing one intensified regimen over 
the other were expected longer survival rates (47%), a 
more favorable toxicity profile (44%), and restrictions 
due to the patients’ performance status (42%), the latter 
leading to the administration of gemcitabine + nab-pacli-
taxel.
 National Preferences for Choosing Intensified 
Chemotherapy 
 We found some differences in the answers with respect 
to the country of origin, specialty, and hospital setting of 
the responders. From a geographical perspective, only 
countries with 5 or more answers were considered in-
cluding Italy ( n = 61), Germany ( n = 35), Spain ( n = 12), 
the United Kingdom ( n = 9), Sweden ( n = 7), and France 
( n = 6). Whereas a majority of physicians from Italy ( n = 
38 out of 61), Spain ( n = 8/12), and the United Kingdom 
( n = 5/9) used gemcitabine + nab-paclitaxel as first-line 
therapy, FOLFIRINOX was predominantly used in 
 Germany ( n = 20/35) and France ( n = 4/6;  Fig. 1 c). In 
Sweden, gemcitabine +/– erlotinib is still the most fre-
quently applied palliative treatment ( n = 3/7). The fre-
quency of using intensified regimens was the highest in 
Spain (>50% of cases;  n = 9/12) and the lowest in Sweden 
(>50% of cases;  n = 1/7). The favored intensified regimen 
differed by country with Italian, Spanish, and Swedish 
physicians preferring gemcitabine + nab-paclitaxel and 
German, French, and British doctors use FOLFIRINOX 
more frequently ( Fig. 1 d).
 Estimated Toxicity Profile 
 Based on the participants’ experience, the toxicity 
 profile of intensified chemotherapy was reported to be 
similar for either regimen, with neutropenia being the 
most common adverse event (88% FOLFIRINOX, 68% 
gemcitabine + nab-paclitaxel), followed by polyneuropa-
thy (42%  FOLFIRINOX, 41% gemcitabine + nab-pacli-
taxel) and rapid deterioration of performance (42% 
 FOLFIRINOX, 31% gemcitabine + nab-paclitaxel). Over-
Table 1.  Distribution of responses by country
Country Number (%)
Italy 61 (39.9)
Germany 35 (22.9)
Spain 12 (7.8)
UK 9 (5.9)
Sweden 7 (4.6)
France 6 (3.9)
Hungary 5 (3.3)
Netherlands 3 (2.0)
Czech 2 (1.3)
Finland 2 (1.3)
Romania 2 (1.3)
Russia 2 (1.3)
Belarus 1 (0.7)
Belgium 1 (0.7)
Latvia 1 (0.7)
Norway 1 (0.7)
Portugal 1 (0.7)
Turkey 1 (0.7)
Ukraine 1 (0.7)
Total 153
Table 2.  Distribution of responses by hospital setting specialty and 
annual case load
Hospital setting Number (%)
Academic 97 (63.4)
Non-academic tertiary center 25 (16.3)
District hospital 24 (15.7)
Outpatient setting 3 (2.0)
Other 4 (2.6)
Specialty
Oncology 78 (51.0)
Surgery 31 (20.3)
Gastroenterology 42 (27.5)
Other 2 (1.3)
Annual case load
<25 73 (47.7)
25–50 54 (35.3)
>50 26 (17.0)
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all, the likelihood of deviating from the original protocol 
by adjusting, interrupting, or deescalating treatment was 
higher when using FOLFIRINOX compared to nab-pacli-
taxel ( Fig. 1 e,  p  < 0.01).
 Second-Line Treatment 
 Notably, the choice of second-line treatment in need of 
de-escalation varied, according to which intensified regi-
men was used as first line. In case of FOLFIRINOX, 39% 
would switch to gemcitabine + nab-paclitaxel, 25% to gem-
citabine +/– erlotinib, and 11% to FOLFOX or FOLFIRI 
respectively ( Fig. 2 a). If gemcitabine + nab-paclitaxel was 
used as first line, 37% would switch to 5-FU or Capecitabine, 
33% choose gemcitabine +/– erlotinib, and only 23% con-
sidered FOLFIRINOX a suitable alternative ( Fig.  2 b). 
When asked about their overall experience with intensified 
chemotherapy in the treatment of metastatic pancreatic 
cancer, responders agreed that patients survived longer 
with acceptable quality of life in 52% of cases when using 
FOLFIRINOX versus 44% for gemcitabine + nab-paclitax-
el. In contrast, 33% replied that patients had longer overall 
survival but significantly increased toxicity, thereby 
 impairing the overall quality of life with  FOLFIRINOX 
versus 12% with gemcitabine + nab-paclitaxel. In contrast, 
11% of responders stated that there is no difference in sur-
vival using gemcitabine + nab-paclitaxel versus 5% with 
 FOLFIRINOX, but acceptable quality of life.
 Preferences According to Specialty and Institution 
 If analyzed according to the respondent’s specialty, it 
appeared as if oncologists ( n = 78) preferred gemcitabine + 
nab-paclitaxel over FOLFIRINOX (61 vs. 34%) as first-
line therapy, whereas gastroenterologists ( n = 42) saw it 
the opposite way (28 vs. 57%). Surgeons ( n = 31) did not 
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 Fig. 1.  a–e Distribution of participating countries (%). All partici-
pants answering question 6: What is current first-line chemotherapy 
regimen of choice for treating patients with metastatic pancreatic 
cancer in your center? Answers to question 6 according to country: 
What is current first-line chemotherapy regimen of choice for treat-
ing patients with metastatic pancreatic cancer in your center? An-
swers to question 9 according to country: Which is the favored che-
motherapeutic regimen among the combination protocols? An-
swers to question 11: rate of deviation from the original treatment 
protocol due to complications or toxicity when using intensified che-
motherapy in metastatic pancreatic cancer in case of FOLFIRINOX 
or gemcitabine + nab-paclitaxel.  *  p  < 0.01 using unpaired  t test. 
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state a preference (38 vs. 35%;  Fig.  3 a). Similar results 
were obtained when physicians were asked for their fa-
vored intensified regimen. The specialty also influenced 
the frequency with which intensified regimens were used. 
Oncologists said they use intensified chemotherapy in 
more than half of their patients in 55%. In contrast, only 
29% of surgeons and 38% of gastroenterologists used 
those therapies in more than half their patients.
 Interestingly, the use of palliative chemotherapy in pa-
tients with pancreatic cancer was influenced by the institu-
tional set up. The most frequently used first-line therapy in 
academic centers ( n = 97) was FOLFIRINOX (51%), where-
as gemcitabine + nab-paclitaxel was the preferred option at 
non-academic tertiary ( n = 25) or district hospitals ( n = 24; 
64 and 58%;  Fig. 3 b). The percentage of doctors using in-
tensified chemotherapy in more than half of their patients 
was the lowest at non-academic tertiary hospitals (12%) 
and similar at academic and district hospitals (49 and 58%).
 Nutritional Support and Future Clinical Trials 
 Overall, 73% of responders said that nutritional sup-
port was part of the standard protocol treatment when 
FOLFIRINOX is used, whereas 64% said so when using 
gemcitabine + nab-paclitaxel. A majority of participants 
(57%) thought that gemcitabine + nab-paclitaxel should 
be used as the backbone for further clinical trials in pa-
tients with metastatic pancreatic cancer.
 Discussion 
 This is an open questionnaire study conducted in 19 
European countries, which aims to understand the 
 current practice and decision-making process of physi-
cians treating patients with metastatic pancreatic can-
cer. It is, to the best of our knowledge, the first study 
to  explore physicians’ experiences and preferences 
2nd line after FOLFIRINOX
Other
15%
Gemcitabine +
nab-paclitaxel 39%
Gemcitabine+/–
erlotinib 25%
FOLFOX/FOLFIRI
11%
a
Other
7%
5-FU or
capecitabine
37%
Gemcitabine+/–
erlotinib 33%
FOLFIRINOX 23%
2nd line after Gemcitabine + nab-paclitaxel
b
 Fig. 2.  a ,  b Answers to question 13: What is 
your second-line treatment of choice after 
de-escalating following FOLFIRINOX 
first-line therapy and gemcitabine + nab-
paclitaxel first-line therapy. 
a
Al
l
100
50
0
%
On
co
lo
gy
Su
rg
er
y
Ga
str
oe
nt
or
ol
og
y
b
100
%
50
0
Al
l
Ac
ad
em
ic
Di
str
ict
No
n-
ac
ad
em
ic
te
rti
ar
y
Gemcitabine – Nab
FOLFIRINOX
Gemcitabine +/–
Erlotinib
 Fig. 3.  a ,  b Answers to question 6 according 
to specialty: What is current first-line che-
motherapy regimen of choice for treating 
patients with metastatic pancreatic cancer 
at your center? Answers to question 6 ac-
cording to hospital setting: What is the cur-
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with  the newly available intensified chemotherapeu-
tic  options for metastatic pancreatic cancer in daily 
 routine.
 The results from published randomized trials seemed 
to reflect the day-to-day experience of many participants 
in this survey. The criteria for choosing one intensified 
regimen over the other were patients’ performance status 
and expected toxicity versus the potential longer life ex-
pectancy. Based on the experience of the participants of 
this questionnaire, FOLFIRINOX was more toxic and as-
sociated with a higher burden of adverse events as reflect-
ed in the estimated higher likelihood of protocol devia-
tion and higher rates of neutropenia, polyneuropathy, 
worsening performance status, and need for nutritional 
support. In the original phase III trial by Conroy et al, 
which led to the approval of FOLFIRINOX, rates of grade 
3 or 4 neutropenia, neuropathy, and diarrhea were re-
ported to be as high as 45, 9.1, and 12.7%  [11] , whereas 
the administration of gemcitabine + nab-paclitaxel in the 
MPACT trial caused less neutropenia and diarrhea (38 
and 6%) but more frequently neuropathy (17%)  [12] . Ac-
cordingly, 39% of the survey participants answered that 
they considered gemcitabine + nab-paclitaxel a suitable 
de-escalation regimen after FOLFIRINOX first-line ther-
apy, but only 23% would do it vice versa. This finding is 
particularly interesting as it indicates that by switching 
between intensified regimens, many participants do not 
follow current international guidelines  [14, 15] . Whether 
administering intensified regimens as second-line treat-
ment really qualifies as de-escalation remains a matter of 
ongoing debate.
 Despite the higher toxicity, participants rated 
 FOLFIRINOX over gemcitabine + nab-paclitaxel in 
achieving longer survival with acceptable quality of life. 
This finding is supported by previously reported data 
where the quality of life impairment had been found to be 
reduced in patients treated with FOLFIRINOX compared 
to gemcitabine alone as part of the original phase II/III 
study  [11, 16] . The effect of nab-paclitaxel in combina-
tion with gemcitabine on overall quality of life has not 
been investigated so far. However, it has also been dem-
onstrated from a registry-based retrospective study that 
simply meeting the eligibility criteria for either of the 2 
intensified regimens as set in the phase III trials will be 
associated with longer survival, even without receiving 
the drug  [17] . The results from this questionnaire thus 
also reflect a clinical dilemma. Since the  FOLFIRINOX 
trial excluded patients with an ECOG of less than 1 or age 
greater 75 years, a comparison of the 2 intensified regi-
mens is difficult to make. Based on these data most clini-
cians and most guidelines will restrict the use of FOL-
FIRINOX to patients with good to excellent performance 
status  [18, 19] , without knowing whether patients who do 
less well, but still qualify for nab-paclitaxel, would in fact 
also benefit from FOLFIRINOX. Interestingly, a recent 
analysis by the National Institute for Health and Care Ex-
cellence in England concluded that there was not enough 
evidence available supporting that patients with a Kar-
nofsky performance status of 70 or 80 would truly benefit 
from nab-paclitaxel + gemcitabine as compared to gem-
citabine alone and questioned the usefulness of perfor-
mance status to allocate patients to different lines of treat-
ment. In the same analysis, a direct comparison of the 2 
study cohorts from the Conroy and von Hoff trials showed 
that apart from age, there were no significant differences 
in non-subjective patient characteristics  [20] .
 A by-country-analysis of answers showed some re-
gional differences reflecting differing national guidelines 
and preferences. This observation may be affected by the 
fact that the FOLFIRINOX trial was conducted in France, 
whereas the MPACT trial was a multinational trial. The 
finding that more than half of the responders from the 
United Kingdom used gemcitabine + nab-paclitaxel as 
first-line therapy, but preferred FOLFIRINOX over gem-
citabine + nab-paclitaxel if asked for their favored com-
bination protocol, can to some extent be explained by 
sampling error, caused by the low number of responses 
from Britain ( n = 9). The fact that oncologists where more 
likely to apply gemcitabine + nab-paclitaxel and gastro-
enterologists preferred FOLFIRINOX is intriguing and 
may be influenced by the respective specialty, which is 
predominantly involved in the care of pancreatic cancer 
patients. In Italy, where nab-paclitaxel is widely used as 
first-line, oncologists are the predominant specialty treat-
ing metastatic pancreatic cancer. On the other hand, in 
Germany, where FOLFIRINOX is widely applied, next to 
hemato-oncologists, gastroenterologists are involved to a 
large extent in the care for pancreatic cancer patients. The 
reason why FOLFIRINOX was more widely applied at 
academic centers compared to non-academic institution 
remains unclear. One could speculate that such institu-
tions would have more experience in treating pancreatic 
cancer patients due to their higher case load and might 
therefore be willing to treat them more aggressively. A 
similar tendency was found in a survey conducted in 2007 
among German doctors who were medically treating pa-
tients with pancreatic cancer in the palliative intent  [21] , 
which showed that high-volume centers treating more 
than 30 patients per year were more likely to apply a com-
bination regimen in patients with good performance sta-
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tus as compared to low-volume centers treating less than 
5 patients annually (61 vs. 44%) Vice versa those 
 low-volume centers tended to always apply monotherapy 
as compared to high-volume centers (39 vs. 18%). The 
same trend was observed when comparing academic cen-
ters to private practice settings. By that time, the most 
commonly applied combinations were gemcitabine with 
oxaliplatin or erlotinib and gemcitabine alone for mono-
therapy  [21] .
 One obvious limitation of our study was the fact that 
the overall response rate was poor and greatly differed by 
country, accounting for almost two-thirds of valid an-
swers originating from only 2 countries and despite our 
efforts, some large European countries are not represent-
ed at all. In order to balance this uneven distribution, we 
conducted a second call for participation via e-mail; how-
ever, the overall response rate remained poor. Therefore, 
our results regarding national preferences of intensified 
chemotherapies must be interpreted with great care and 
cannot be generalized. In spite of this limitation, we be-
lieve this study provides a general overview and outlook, 
thereby creating the needed opportunity to conduct fur-
ther studies and discussion on the real world use of inten-
sified palliative chemotherapy for pancreatic cancer. Oth-
er potential biases include the overrepresentation of aca-
demic physicians, as this might not reflect the common 
practice in many places. Further, the responders were not 
blinded to the results of the clinical trials discussed above; 
thus, despite asking for personal experience, answers 
could have been influenced by the respondents’ percep-
tion of the published trial data with regards to efficacy and 
toxicity of the respective regimen as well as bias by recall.
 We conclude that shortly after the introduction of in-
tensified chemotherapies as first-line treatment for meta-
static pancreatic cancer in Europe, both FOLFIRINOX 
and gemcitabine + nab-paclitaxel are widely available 
throughout Europe and used at almost the same  frequency. 
A majority of the participants in this European question-
naire study believe that future clinical trials should be 
based on the use of gemcitabine + nab-paclitaxel.
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